Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind crossover trial of OC000459 in allergic asthma
2005-005838-12Phase 2Completed
- Sponsor
- Oxagen
- Start
- Jan 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of timapiprant in allergic asthma and asthma (2 arms), sponsored by Oxagen. Primary endpoint: Late asthmatic response diminution (AUC and maximum percentage FEV1 reduction 4-10 hours post-allergen). Started Jan 2006; status: completed.
02
Drugs
timapiprant
03
Conditions
allergic asthmaasthma
Beyond the preview
Go deeper on 2005-005838-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-005838-12.